MBX Biosciences (MBX) Institutional Ownership $7.38 -0.05 (-0.67%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$7.38 0.00 (-0.07%) As of 04/15/2025 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for MBX Biosciences (NYSE:MBX)Number ofInstitutional Buyers(last 12 months)38TotalInstitutional Inflows(last 12 months)$413.90MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$6.00M Get MBX Insider Trade Alerts Want to know when executives and insiders are buying or selling MBX Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data MBX Institutional Buying and Selling by Quarter Remove Ads MBX Biosciences Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails3/24/2025Wellington Management Group LLP2,909,639$52.99M0.0%-1.0%8.705% 2/17/2025Woodline Partners LP608,721$11.22M0.1%+17.1%1.821% 2/17/2025Parkman Healthcare Partners LLC170,000$3.13M0.4%N/A0.509% 2/17/2025Nuveen Asset Management LLC14,471$267K0.0%N/A0.043% 2/17/2025Millennium Management LLC333,642$6.15M0.0%-24.2%0.998% 2/17/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.6,335$117K0.0%N/A0.019% 2/17/2025Deutsche Bank AG4,338$80K0.0%N/A0.013% 2/17/2025Driehaus Capital Management LLC1,581,760$29.15M0.2%+61.2%4.733% 2/17/2025Citadel Advisors LLC220,330$4.06M0.0%+62.5%0.659% 2/17/2025Bank of America Corp DE16,059$296K0.0%N/A0.048% Get the Latest News and Ratings for MBX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for MBX Biosciences and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025BNP Paribas Financial Markets1,486$27K0.0%N/A0.004% 2/17/2025Alyeska Investment Group L.P.174,700$3.22M0.0%-22.4%0.523% 2/14/2025Schonfeld Strategic Advisors LLC71,500$1.32M0.0%N/A0.214% 2/14/2025Northern Trust Corp90,682$1.67M0.0%N/A0.271% 2/14/2025The Manufacturers Life Insurance Company 49,675$916K0.0%+7.5%0.149% 2/14/2025Virtus ETF Advisers LLC3,468$64K0.0%N/A0.010% 2/14/2025Price T Rowe Associates Inc. MD1,161,527$21.41M0.0%-2.6%3.476% 2/14/2025MetLife Investment Management LLC7,230$133K0.0%N/A0.022% 2/13/2025Marshall Wace LLP25,900$477K0.0%+115.8%0.077% 2/13/2025Wells Fargo & Company MN5,844$108K0.0%N/A0.017% 2/12/2025Geode Capital Management LLC265,703$4.90M0.0%+1,093.2%0.795% 2/12/2025Franklin Resources Inc.369,300$6.81M0.0%-17.9%1.105% 2/12/2025Wellington Management Group LLP2,909,639$52.99M0.0%-1.0%8.706% 2/12/2025Norges Bank25,000$461K0.0%N/A0.075% 2/12/2025BIT Capital GmbH12,743$235K0.0%N/A0.038% 2/12/2025JPMorgan Chase & Co.9,106$168K0.0%N/A0.027% 2/11/2025Corebridge Financial Inc.5,593$103K0.0%N/A0.017% 2/11/2025Platinum Investment Management Ltd.162,090$2.99M0.2%+8.1%0.485% 2/6/2025Charles Schwab Investment Management Inc.93,311$1.72M0.0%N/A0.279% 2/4/2025Bank of New York Mellon Corp23,914$441K0.0%N/A0.072% 1/30/2025 Rhumbline Advisers9,472$175K0.0%N/A0.028% 11/27/2024Franklin Resources Inc.450,000$11.69M0.0%N/A1.347% 11/19/2024Barclays PLC16,400$426K0.0%N/A0.049% 11/18/2024Teachers Retirement System of The State of Kentucky26,708$694K0.0%N/A0.080% 11/16/2024Geode Capital Management LLC22,269$579K0.0%N/A0.067% 11/15/2024Frazier Life Sciences Management L.P.5,985,347$155.50M6.2%N/A17.909% 11/15/2024Barclays PLC16,400$426K0.0%N/A0.049% 11/15/2024Jane Street Group LLC26,570$690K0.0%N/A0.080% 11/15/2024Wellington Management Group LLP2,937,853$74.26M0.0%N/A8.791% 11/15/2024Soros Fund Management LLC30,000$779K0.0%N/A0.090% Two Unmistakable Patterns Return… (Ad)The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at record pace. Why massive amounts of gold are being moved between countries. Why governments are repositioning their gold reserves. But here's what most people miss, the second pattern: During these resets, a unique anomaly appears in certain gold mining stocks. I call it the "Golden Anomaly."Each one is trading at up to an 95% discount to their true value. Click here to see the pattern bef11/15/2024RA Capital Management L.P.1,511,334$39.26M0.5%N/A4.522% 11/15/2024Point72 DIFC Ltd24,011$624K0.0%N/A0.072% 11/15/2024Point72 Asset Management L.P.15,600$405K0.0%N/A0.047% 11/15/2024Maven Securities LTD50,000$1.30M0.0%N/A0.150% 11/15/2024Point72 Asia Singapore Pte. Ltd.10,706$278K0.1%N/A0.032% 11/14/2024NEA Management Company LLC3,614,486$93.90M5.1%N/A10.816% 11/13/2024The Manufacturers Life Insurance Company46,194$1.20M0.0%N/A0.138% (Data available from 1/1/2016 forward)Remove Ads MBX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of MBX shares? During the previous two years, 41 institutional investors and hedge funds held shares of MBX Biosciences. The most heavily invested institutionals were Frazier Life Sciences Management L.P. ($155.50M), NEA Management Company LLC ($93.90M), Wellington Management Group LLP ($52.99M), RA Capital Management L.P. ($39.26M), Driehaus Capital Management LLC ($29.15M), Price T Rowe Associates Inc. MD ($21.41M), and Woodline Partners LP ($11.22M).Learn more on MBX's institutional investors. Which institutional investors have been buying MBX Biosciences stock? Of the 38 institutional investors that purchased MBX Biosciences stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Frazier Life Sciences Management L.P. ($5.99M), NEA Management Company LLC ($3.61M), Wellington Management Group LLP ($2.94M), RA Capital Management L.P. ($1.51M), Driehaus Capital Management LLC ($600.44K), Franklin Resources Inc. ($450K), and Geode Capital Management LLC ($265.70K). How much institutional buying is happening at MBX Biosciences? Institutional investors have bought a total of 16,401,541 shares in the last 24 months. This purchase volume represents approximately $413.90M in transactions. Which MBX Biosciences major shareholders have been selling company stock? The following institutional investors have sold MBX Biosciences stock in the last 24 months: Millennium Management LLC ($106.77K), Franklin Resources Inc. ($80.70K), Wellington Management Group LLP ($56.43K), Alyeska Investment Group L.P. ($50.30K), and Price T Rowe Associates Inc. MD ($31.41K). How much institutional selling is happening at MBX Biosciences? Institutional investors have sold a total of 325,608 shares in the last 24 months. This volume of shares sold represents approximately $6.00M in transactions. Related Companies 89bio Institutional Ownership Chimerix Institutional Ownership Avid Bioservices Institutional Ownership Arcus Biosciences Institutional Ownership Vir Biotechnology Institutional Ownership Mineralys Therapeutics Institutional Ownership Phibro Animal Health Institutional Ownership Spyre Therapeutics Institutional Ownership Nurix Therapeutics Institutional Ownership Zymeworks Institutional Ownership This page (NYSE:MBX) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.